27569995|t|Antidepressant -like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495
27569995|a|Clinical studies have shown that the muscarinic receptor antagonist scopolamine induces a potent and rapid antidepressant effect relative to conventional antidepressants. However, potential undesirable effects, including memory impairment, partially limit the use of scopolamine in psychiatry. In the present study, we propose to overcome these limitations and enhance the therapeutic effects of scopolamine via administration in combination with the group II metabotropic glutamate (mGlu) receptor antagonist, LY341495. Joint administration of sub-effective doses of scopolamine (0.03 or 0.1 mg/kg, i.p.) with a sub-effective dose of LY341495 (0.1 mg/kg, i.p.) induced a profound antidepressant effect in the tail suspension test (TST) and in the forced swim test (FST) in mice. This drug combination did not impair memory, as measured using the Morris water maze (MWM), and did not influence the locomotor activity of mice. Furthermore, we found that an AMPA receptor antagonist, NBQX (10 mg/kg), completely reversed the antidepressant-like activity of a mixture of scopolamine and LY341495 in the TST. However, this effect was not influenced by para-chlorophenylalanine (PCPA) pre-treatment, indicating a lack of involvement of serotonergic system activation in the antidepressant-like effects of jointly given scopolamine and LY341495. Therefore, the combined administration of low doses of the antimuscarinic drug scopolamine and the group II mGlu receptor antagonist LY341495 might be a new, effective and safe strategy in the therapy of depression.
27569995	0	14	Antidepressant	T121	C0003289
27569995	21	31	effects of	T080	C1704420
27569995	32	43	scopolamine	T109,T121	C0036442
27569995	47	51	mice	T015	C0025929
27569995	72	94	group II mGlu receptor	T116,T192	C0206529
27569995	95	105	antagonist	T121	C1254351
27569995	106	114	LY341495	T109,T121	C0757826
27569995	115	131	Clinical studies	T062	C0008972
27569995	152	171	muscarinic receptor	T116,T192	C0034826
27569995	172	182	antagonist	T121	C1254351
27569995	183	194	scopolamine	T109,T121	C0036442
27569995	222	243	antidepressant effect	T033	C0243095
27569995	269	284	antidepressants	T121	C0003289
27569995	305	324	undesirable effects	T169	C0001688
27569995	336	353	memory impairment	T048	C0233794
27569995	355	370	partially limit	T169	C0439801
27569995	382	393	scopolamine	T109,T121	C0036442
27569995	397	407	psychiatry	T091	C0033873
27569995	424	429	study	T062	C2603343
27569995	460	471	limitations	T169	C0449295
27569995	488	507	therapeutic effects	T201	C1527144
27569995	511	522	scopolamine	T109,T121	C0036442
27569995	527	541	administration	T061	C1533734
27569995	545	556	combination	T080	C0205195
27569995	566	613	group II metabotropic glutamate (mGlu) receptor	T116,T192	C0206529
27569995	614	624	antagonist	T121	C1254351
27569995	626	634	LY341495	T109,T121	C0757826
27569995	636	656	Joint administration	T061	C1533734
27569995	660	679	sub-effective doses	T081	C0178602
27569995	683	694	scopolamine	T109,T121	C0036442
27569995	728	746	sub-effective dose	T081	C0178602
27569995	750	758	LY341495	T109,T121	C0757826
27569995	777	784	induced	T169	C0205263
27569995	796	817	antidepressant effect	T033	C0243095
27569995	825	845	tail suspension test	T060	C0683444
27569995	847	850	TST	T060	C0683444
27569995	863	879	forced swim test	T060	C0683444
27569995	881	884	FST	T060	C0683444
27569995	889	893	mice	T015	C0025929
27569995	900	916	drug combination	T121	C0013162
27569995	925	938	impair memory	T048	C0233794
27569995	962	979	Morris water maze	T060	C4277747
27569995	981	984	MWM	T060	C4277747
27569995	1013	1031	locomotor activity	T040	C0023946
27569995	1035	1039	mice	T015	C0025929
27569995	1071	1084	AMPA receptor	T116,T192	C0072899
27569995	1085	1095	antagonist	T121	C1254351
27569995	1097	1101	NBQX	T109,T121	C0045376
27569995	1138	1166	antidepressant-like activity	T033	C0243095
27569995	1172	1179	mixture	T167	C0439962
27569995	1183	1194	scopolamine	T109,T121	C0036442
27569995	1199	1207	LY341495	T109,T121	C0757826
27569995	1215	1218	TST	T060	C0683444
27569995	1234	1240	effect	T080	C1280500
27569995	1263	1287	para-chlorophenylalanine	T116,T121	C0030135
27569995	1289	1293	PCPA	T116,T121	C0030135
27569995	1295	1308	pre-treatment	T079	C2709094
27569995	1346	1376	serotonergic system activation	T044	C1148560
27569995	1384	1411	antidepressant-like effects	T033	C0243095
27569995	1429	1440	scopolamine	T109,T121	C0036442
27569995	1445	1453	LY341495	T109,T121	C0757826
27569995	1470	1493	combined administration	T061	C1533734
27569995	1497	1506	low doses	T081	C0178602
27569995	1514	1533	antimuscarinic drug	T121	C0003385
27569995	1534	1545	scopolamine	T109,T121	C0036442
27569995	1554	1576	group II mGlu receptor	T116,T192	C0206529
27569995	1577	1587	antagonist	T121	C1254351
27569995	1588	1596	LY341495	T109,T121	C0757826
27569995	1613	1622	effective	T080	C1280519
27569995	1632	1640	strategy	T170	C0679716
27569995	1648	1655	therapy	T061	C0087111
27569995	1659	1669	depression	T048	C0011570